title: 7(th) International Immunoglobulin Conference: Poster presentations.
abstract: Immunoglobulin (Ig) therapy is the mainstay of treatment for primary antibody deficiency disorders and has proved to be efficacious in specific autoimmune and inflammatory diseases. Additionally, due to the role of Ig in complement activation, it is being used increasingly in solid organ transplantation. Furthermore, Ig is the primary or secondary treatment in some immune-mediated neuropathies such as chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy (MMN). This session discusses trends of Ig use in Europe, proposed mechanisms of action, adverse effects and the potential role of Ig therapy in transplantation. Dr Šedivá reported that Ig therapy is available in all European countries, although dosing is not always optimal, due partly to reimbursement plans. Subcutaneous immunoglobulin (SCIg) has become increasingly accessible in recent years; however, the chosen route of administration still varies widely between countries. Dr Berger's presentation on optimization of Ig therapy in neuropathies, and Dr Rojavin's report on a pharmacometric model to determine the serum IgG levels achieved by different dosing regimens in primary antibody deficiency (PAD) patients, led to the challenging concept of using individualized dosing strategies. Dr Klehmet reported on the potential benefit of using antigen-specific T cell responses as a biomarker of IVIg responsiveness in CIDP patients, while Dr von Gunten provided an insight into the mechanisms of action of Ig preparations, suggesting that the immunoregulatory effects of IgG may be mediated by IgG antibodies against glycans. Dr Basta reported on the potential thrombogenic adverse effects associated with Ig therapy. Although these adverse events are rare, further studies are needed to clarify the relationship between Ig replacement and immunomodulatory therapy and these adverse reactions. In transplantation, Dr Carbone described that prophylactic IVIg treatment was found to decrease the incidence of severe infection in IgG hypogammaglobulinaemia patients undergoing heart transplantations. Furthermore, Dr Clatworthy reported that inactivating polymorphisms in the inhibitory receptor FcγRIIB do not impact upon kidney allograft survival.
authors.affiliation: Centre for Chronic Immunodeficiencies, Freiburg, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Warnatz
authors.forename: M
authors.initials: M
authors.lastname: Ballow
authors.forename: M
authors.initials: M
authors.lastname: Stangel
authors.forename: V
authors.initials: V
authors.lastname: Bril
mesh_terms: D005060:Europe; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D007074:Immunoglobulin G / Q000276:immunology* / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000276:immunology* / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000276:immunology / Q000628:therapy; D014180:Transplantation / Q000009:adverse effects
chemical_list: D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous
keywords: intravenous immunoglobulin; neuropathy; primary immunodeficiency; subcutaneous immunoglobulin; transplantation